Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Specialty pharma focused on
chronic inflammatory diseases –
IPO July 2011 (NASDAQ: HZNP)

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Biomarker-guided therapies
for chronic pain
and inflammation

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Transforming stem cell
transplant therapy for auto-
immune and blood-based diseases

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Next-generation oncolytic
immunotherapies for
cancer treatment

Discovering new medicines
for severe
neurodegenerative diseases

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

First-in-class therapies for severe
obesity and rare genetic conditions –
IPO June 2014 (NASDAQ: ZFGN)

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Universal
cell-based
cancer immunotherapy

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Novel therapeutics
targeting
diseases of aging

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Small molecule
drug design
using statistical modeling

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Next generation
synthetic biology platform
for novel therapeutics

Preventing axonal degeneration
in patients with
neurological diseases

Minimally invasive
heart valve
devices

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

New class of
regulated cell and
gene therapies

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Breakthrough computer-aided
drug design
for transformative medicines

First-in-class
RNA therapies
for severe genetic diseases

Bispecific antibodies
to improve the treatment
of serious diseases

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Cancer immunotherapies
at the interface of
innate & adaptive immunity

Therapies for rare,
debilitating, and underserved
neurological diseases

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Novel therapies
for severe, highly drug-resistant
bacterial infections

Cell and gene therapies
for rare diseases
and cancer

Novel therapeutics using proprietary
computational chemistry –
IPO Sept 2014 (NASDAQ: VTAE)

Behavioral epigenetic therapy
for cognitive
and neurodegenerative disease

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Novel therapeutics for
schizophrenia and other
severe psychiatric diseases